Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.73 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.69 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226005 | 1.00 | ADORA3 (0.73) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12200093 | 1.00 | ADORA3 (0.73) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12200092 | 0.91 | ADORA3 (0.77) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL15080479 | 0.91 | ADORA3 (0.77) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12226792 | 0.91 | ADORA3 (0.77) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12226798 | 0.91 | ADORA3 (0.77) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL15080732 | 0.91 | ADORA3 (0.77) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12200095 | 0.91 | ADORA3 (0.77) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12226865 | 0.89 | ADORA3 (0.75) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A | |
| SCHEMBL12200099 | 0.89 | ADORA3 (0.75) | ADORA3TAS1R3TAS1R1ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-9289383-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289383-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8895530-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895530-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8476247-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885TAS1R3 3530/4885TAS1R1 3537/4885 |
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885TAS1R3 3530/4885TAS1R1 3537/4885 |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885TAS1R3 3530/4885TAS1R1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.